Breakthrough trial aims to halt heart valve disease with cholesterol medication
NCT ID NCT07256197
Summary
This study is testing whether a cholesterol-lowering medication (PCSK9 inhibitor) can slow down the progression of calcific aortic stenosis, a condition where the heart's aortic valve stiffens and narrows. The trial will enroll 160 adults with mild to moderate disease who don't yet need valve replacement surgery. Participants will be randomly assigned to receive either the medication or no medication and followed for 2 years to see if the drug slows the valve's deterioration.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS, CALCIFIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.